Published in J Virol on July 01, 2001
Macrophages archive HIV-1 virions for dissemination in trans. EMBO J (2005) 2.27
Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol (2005) 1.97
Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. J Virol (2007) 1.66
Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. PLoS Pathog (2007) 1.13
Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol (2006) 1.12
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother (2009) 0.96
Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release. J Virol (2008) 0.84
Recent Insights into HIV Accessory Proteins. Curr Infect Dis Rep (2003) 0.78
Vpu Protein: The Viroporin Encoded by HIV-1. Viruses (2015) 0.78
Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology (2015) 0.77
Targeting human immunodeficiency virus type 1 assembly, maturation and budding. Drug Target Insights (2007) 0.77
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol (2000) 6.47
Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol (1999) 4.71
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol (1999) 4.66
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A (1993) 3.63
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology (1994) 3.16
HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med (1999) 3.01
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol (1992) 2.62
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology (1999) 2.27
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J (1997) 2.09
The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol (1996) 2.01
The influenza A virus M2 channel: a molecular modeling and simulation study. Virology (1997) 1.94
Annexins in cell membrane dynamics. Ca(2+)-regulated association of lipid microdomains. J Cell Biol (2000) 1.67
Engagement of GPI-linked CD48 contributes to TCR signals and cytoskeletal reorganization: a role for lipid rafts in T cell activation. Immunity (1998) 1.61
Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol (1995) 1.52
Cell type-dependence for Vpu function. J Med Primatol (1994) 1.47
Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol (1999) 1.39
Membrane permeabilization by small hydrophobic nonstructural proteins of Japanese encephalitis virus. J Virol (1999) 1.25
CD3delta couples T-cell receptor signalling to ERK activation and thymocyte positive selection. Nature (2000) 1.15
Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology (1999) 1.13
Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. J Virol (1999) 1.12
Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques. Virology (1999) 1.06
Identification of regions of poliovirus 2BC protein that are involved in cytotoxicity. J Virol (1998) 1.02
The human immunodeficiency virus type 1 Vpu protein enhances membrane permeability. Biochemistry (1998) 1.01
Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene. AIDS Res Hum Retroviruses (1999) 1.00
Membrane permeability induced by hepatitis A virus proteins 2B and 2BC and proteolytic processing of HAV 2BC. Virology (1998) 0.98
Relationship between productive HIV-1 infection of macrophages and CCR5 utilization. Virology (1999) 0.94
Cofactors for human immunodeficiency virus entry into primary macrophages. J Infect Dis (1999) 0.90
Changes in the host range and growth potential of an HIV-1 clone are conferred by the vpu gene. Virology (1993) 0.89
The N-terminal matrix domain of HIV-1 Gag is sufficient but not necessary for viral protein U-mediated enhancement of particle release through a membrane-targeting mechanism. Virology (2000) 0.89
Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques. Virology (1998) 0.88
Effects of Vpu expression on Xenopus oocyte membrane conductance. Virology (1998) 0.88
Potential for the transmission of HIV-1 despite highly active antiretroviral therapy. N Engl J Med (1998) 0.84
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol (1992) 5.19
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol (1993) 4.16
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc Natl Acad Sci U S A (1989) 3.65
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity. Virology (1986) 3.15
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol (1997) 3.07
Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol (1992) 2.62
Characterization of long terminal repeat sequences of HTLV-III. Science (1985) 2.56
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J (1998) 2.56
Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1995) 2.43
Human-proto-oncogene nucleotide sequences corresponding to the transforming region of simian sarcoma virus. Science (1984) 2.32
Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J Virol (1989) 2.28
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology (1994) 2.14
HTLV-III, LAV, ARV are variants of same AIDS virus. Nature (1985) 2.03
Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood (1998) 2.03
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol (1999) 2.02
Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res (1985) 2.01
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol (2006) 2.00
Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol (1999) 1.94
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Sequences of the 5' portion of the human c-sis gene: characterization of the transcriptional promoter and regulation of expression of the protein product by 5' untranslated mRNA sequences. Nucleic Acids Res (1987) 1.91
Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature (1984) 1.73
Multidrug resistance transporters and modulation. Curr Opin Oncol (2000) 1.71
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem (1998) 1.68
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses (1989) 1.67
Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med (1999) 1.63
Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol (2000) 1.61
Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells. J Virol (1992) 1.59
Transforming potential of human c-sis nucleotide sequences encoding platelet-derived growth factor. Science (1984) 1.58
Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol (1996) 1.55
Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci U S A (1990) 1.54
Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J Virol (1998) 1.52
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc Natl Acad Sci U S A (1989) 1.47
Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol (1996) 1.45
Analysis of the function of viral protein X (VPX) of HIV-2. Virology (1989) 1.42
HIV-2 viral protein X association with the GAG p27 capsid protein. Virology (1994) 1.35
Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol (2000) 1.34
In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1. J Virol (1996) 1.33
Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. J Virol (2004) 1.32
Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology (1993) 1.32
The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J Virol (2000) 1.29
Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J Virol (1996) 1.27
Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci U S A (1991) 1.27
Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients. Virology (1991) 1.24
Nucleotide sequence analysis of a variant human T-cell leukemia virus (HTLV-Ib) provirus with a deletion in pX-I. J Virol (1985) 1.23
Nucleotide sequence of transforming human c-sis cDNA clones with homology to platelet-derived growth factor. Nucleic Acids Res (1985) 1.18
Endovascular gastrointestinal stapler device malfunction during laparoscopic nephrectomy: early recognition and management. J Urol (2000) 1.15
Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage. J Virol (1992) 1.15
Specificity of polymerase chain amplification reactions for human immunodeficiency virus type 1 DNA sequences. AIDS Res Hum Retroviruses (1989) 1.15
Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest. Virology (1998) 1.14
Role of asparagine-linked glycosylation in human immunodeficiency virus type 1 transmembrane envelope function. Virology (1992) 1.14
Interferon, double-stranded RNA and RNA degradation. Characteristics of an endonuclease activity. Eur J Biochem (1977) 1.14
Particle assembly and Vpr expression in human immunodeficiency virus type 1-infected cells demonstrated by immunoelectron microscopy. J Gen Virol (1994) 1.14
The HTLV receptor is a widely expressed protein. Virology (2000) 1.13
Killing of primary CD4+ T cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 1.12
Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS (1993) 1.09
Proliferation response to interleukin-2 and Jak/Stat activation of T cells immortalized by human T-cell lymphotropic virus type 1 is independent of open reading frame I expression. J Virol (1999) 1.07
The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood (2001) 1.07
Phosphorylation of human immunodeficiency virus type 1 Vpr regulates cell cycle arrest. J Virol (2000) 1.05
HIV-1 Nef protein inhibits the recruitment of AP-1 DNA-binding activity in human T-cells. Virology (1993) 1.04
Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization. J Virol (1991) 1.03
Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. J Virol Methods (2000) 1.02
Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virol Methods (1998) 1.01
Identification of HIV1 determinants for T lymphoid cell line infection. Virology (1993) 1.00
Human immunodeficiency virus type 1 Nef protein down-regulates transcription factors NF-kappa B and AP-1 in human T cells in vitro after T-cell receptor stimulation. J Virol (1994) 1.00
HIV-1 Nef protein downregulation of CD4 surface expression: relevance of the lck binding domain of CD4. Virology (1995) 0.99
Cytotoxic factors secreted by cells infected by human immunodeficiency virus type I. AIDS Res Hum Retroviruses (1987) 0.98
Attenuation of HIV-1 infectivity by an inhibitor of oligosaccharide processing. AIDS Res Hum Retroviruses (1990) 0.98
Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors. J Virol (2001) 0.96
Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants. J Virol (1991) 0.96
Evolution of sequence divergence among human immunodeficiency virus type 1 isolates derived from a blood donor and a recipient. Pediatr Res (1993) 0.96
Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS (1994) 0.95
Human immunodeficiency virus type 2 Vpx-Gag interaction. J Virol (1998) 0.95
Differences among HIV-1 variants in their ability to elicit secretion of TNF-alpha. J Immunol (2000) 0.95
HIV type 2 Vpx interaction with Gag and incorporation into virus-like particles. AIDS Res Hum Retroviruses (2001) 0.94
Relationship between productive HIV-1 infection of macrophages and CCR5 utilization. Virology (1999) 0.94
Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant (2011) 0.94
Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. J Virol (2009) 0.93
Highly localized tracks of human immunodeficiency virus type 1 Nef in the nucleus of cells of a human CD4+ T-cell line. Proc Natl Acad Sci U S A (1993) 0.93
The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway. J Virol (1993) 0.92
Nef and LTR sequence variation from sequentially derived human immunodeficiency virus type 1 isolates. Virology (1995) 0.91
Regulation of human immunodeficiency virus Nef protein by phosphorylation. Virology (1994) 0.91
Role of HIV-1 envelope V3 loop cleavage in cell tropism. AIDS Res Hum Retroviruses (1993) 0.91
Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood (1997) 0.91
Apocrine adenocarcinoma presenting as a large ulcerated axillary mass. Dermatol Surg (1997) 0.91